U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. FDA alerts consumers of BioLyte Laboratories voluntary recall of NeoRelief
  1. Drug Safety and Availability

FDA alerts consumers of BioLyte Laboratories voluntary recall of NeoRelief

[9/14/2018] The Food and Drug Administration is alerting consumers and health care professionals about a voluntary recall of certain lots (1138, 1139, 1146, and 1160) of NeoRelief distributed by BioLyte Laboratories (Grand Rapids, Michigan). NeoRelief is labeled as a homeopathic topical for the temporary relief of occasional muscle cramps, restlessness and twitching and is being recalled due to microbial contamination at the active ingredient manufacturing facility.

Administration or use of drug products with microbial contamination could potentially result in increased infections that may require medical intervention.

Some of NeoRelief’s active ingredients were manufactured at a King Bio Inc. facility in Asheville, North Carolina. Previously, FDA alerted consumers of HelloLife’s voluntary recall of drug products labeled as homeopathic and Beaumont Bio Med’s voluntary recall of all water- and alcohol-based products, which are also manufactured by King Bio.

Health care professionals and patients are encouraged to report any adverse events associated with Beaumont’s drug products to the FDA’s MedWatch Adverse Event Reporting program:

Back to Top